دورية أكاديمية
Leveraging Molecular Diagnostic Technologies to Close the Global Cancer Pathology Gap.
| العنوان: | Leveraging Molecular Diagnostic Technologies to Close the Global Cancer Pathology Gap. |
|---|---|
| المؤلفون: | Erfani P; Harvard Medical School, Boston, MA., Bates M; Medical and Scientific Affairs, Oncology, Cepheid, Sunnyvale, CA., Garcia-Gonzalez P; The Max Foundation, Global Headquarters, Seattle, WA., Milner DA; American Society for Clinical Pathology, Chicago, IL.; Harvard TH Chan School of Public Health, Boston, MA., Rebbeck TR; Harvard TH Chan School of Public Health, Boston, MA., Ruhangaza D; Department of Pathology, Butaro Cancer Center of Excellence, Burera, Rwanda., Shulman LN; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Fadelu T; Harvard Medical School, Boston, MA.; Dana-Farber Cancer Institute, Boston, MA. |
| المصدر: | JCO global oncology [JCO Glob Oncol] 2022 Oct; Vol. 8, pp. e2200182. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101760170 Publication Model: Print Cited Medium: Internet ISSN: 2687-8941 (Electronic) Linking ISSN: 26878941 NLM ISO Abbreviation: JCO Glob Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Alexandria, VA : American Society of Clinical Oncology, [2020]- |
| مواضيع طبية MeSH: | Neoplasms*/diagnosis , Neoplasms*/therapy , Pathology, Molecular*, Humans ; Technology |
| مستخلص: | Competing Interests: Michael BatesEmployment: Cepheid/DanaherStock and Other Ownership Interests: Danaher Dan A. MilnerThis author is a member of the JCO Global Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.Employment: Libragem Consulting LLC Timothy R. RebbeckHonoraria: AstraZenecaConsulting or Advisory Role: AstraZeneca Lawrence N. ShulmanThis author is a member of the JCO Global Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: GenentechResearch Funding: Celgene (Inst), Independence Blue Cross (Inst) Temidayo FadeluResearch Funding: Celgene (Inst), Cepheid (Inst)No other potential conflicts of interest were reported. |
| References: | Gates Open Res. 2018 Jul 25;2:35. (PMID: 30234198) Womens Health (Lond). 2020 Jan-Dec;16:1745506520914804. (PMID: 32364058) Cost Eff Resour Alloc. 2021 Mar 12;19(1):18. (PMID: 33712039) Annu Rev Pathol. 2022 Jan 24;17:387-402. (PMID: 35073168) BMC Infect Dis. 2017 Jan 21;17(1):91. (PMID: 28109255) JCO Glob Oncol. 2020 Aug;6:1352-1356. (PMID: 32886559) EClinicalMedicine. 2020 Jan 26;19:100257. (PMID: 32140674) JCO Glob Oncol. 2021 Apr;7:611-621. (PMID: 33909482) Lancet Glob Health. 2020 Feb;8(2):e296-e304. (PMID: 31981559) Blood Adv. 2021 May 25;5(10):2447-2455. (PMID: 33988700) J Glob Oncol. 2015 Sep 23;1(1):37-45. (PMID: 28804770) Am J Clin Pathol. 2021 Oct 13;156(5):766-776. (PMID: 34050358) J Glob Oncol. 2018 Sep;4:1-6. (PMID: 30241211) PLoS Med. 2014 Nov 25;11(11):e1001760. (PMID: 25423041) PLoS One. 2015 Jun 15;10(6):e0123536. (PMID: 26075722) N Engl J Med. 2010 Sep 9;363(11):1070-1. (PMID: 20825320) Adm Policy Ment Health. 2011 Mar;38(2):65-76. (PMID: 20957426) J Clin Oncol. 2016 Jan 1;34(1):69-75. (PMID: 26578613) |
| تواريخ الأحداث: | Date Created: 20221017 Date Completed: 20221019 Latest Revision: 20230106 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC9812500 |
| DOI: | 10.1200/GO.22.00182 |
| PMID: | 36252158 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2687-8941 |
|---|---|
| DOI: | 10.1200/GO.22.00182 |